Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms
Sign Up to like & getrecommendations! Published in 2021 at "Pancreas"
DOI: 10.1097/mpa.0000000000001794
Abstract: Objectives Checkpoint inhibitors (CPIs) for low- and intermediate-grade neuroendocrine tumors (NETs) have been associated with limited efficacy; recent studies suggest CPIs may represent promising treatment for high-grade neuroendocrine neoplasms (NENs). Methods We examined 57 patients… read more here.
Keywords: patients poorly; checkpoint inhibitors; efficacy; neuroendocrine neoplasms ... See more keywords
TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC
Sign Up to like & getrecommendations! Published in 2020 at "Oncotarget"
DOI: 10.18632/oncotarget.27430
Abstract: Introduction: The impact of TP53 co-mutations in EGFR mutated patients on PFS and OS is controversial. Different classifications of TP53 mutations with respect to functional and potential clinical impact have been published. Therefore, we retrospectively… read more here.
Keywords: egfr mutated; mutations egfr; tp53 mutations; orr pfs ... See more keywords